Literature DB >> 27658417

Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission.

Y El Miedany1,2,3, M El Gaafary4, S Youssef5, I Ahmed6, Sami Bahlas7, M Hegazi8, A Nasr9.   

Abstract

This study aims to assess clinical, lab/immunological or imaging (joint ultrasonography) markers able to predict disease relapse in RA patients in sustained remission when tapering or stopping their treatment. One hundred fifty-seven RA patients in clinical remission (DAS-28 <2.6 for >6 months), receiving treatment with sDMARDs and bDMARD therapy, were randomly allocated into any of five groups: Group 1: continue full dose DMARDs and taper biologic therapy by 50 % (31 patients); Group 2: taper both DMARDs and biologic therapy dose by 50 % (32 patients); Group 3: taper DMARDs by 50 % and stop biologic therapy (31 patients); Group 4: stop both DMARDs and biologic therapy (31 patients); Group 5: continue medications without change (31 patients). Forty joints were assessed ultrasonographically (DAS-28 joints + ankles + metatarsophalangeal joints) and prospectively monitored for 12 months. The primary endpoint was sustained remission for 12 months. Patients were considered as having a relapse when the DAS-28 score was >3.2 and anti-rheumatic treatment was escalated. The frequency of relapse was 41.9 % in Group 1, 59.3 % in Group 2, 67.7 % in Group 3, 77.4 % in Group 4 and 6.5 % in Group 5. Relapse rates were significantly higher in patients whose ultrasound scores raised within 3 months of stopping their medications (P < 0.001 for both GS and PD scores). Cox regression identified ACPA positivity (at baseline) and progression of functional disability (at 2 months) as predictors for relapse. Tapering therapy is feasible in RA patients. Tailored dynamic approach is advised. Joint ultrasonographic assessment, ACPA positivity and worsening functional disability predicted relapse within a short term after discontinuation of the treatment. RA patients whose DAS-28 score was <2 were more likely to remain in remission.

Entities:  

Keywords:  Early arthritis; Joint; Remission; US

Mesh:

Substances:

Year:  2016        PMID: 27658417     DOI: 10.1007/s10067-016-3413-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  32 in total

1.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

2.  Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis.

Authors:  Giusy Peluso; Alessandro Michelutti; Silvia Bosello; Elisa Gremese; Barbara Tolusso; Gianfranco Ferraccioli
Journal:  Ann Rheum Dis       Date:  2010-11-19       Impact factor: 19.103

3.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

4.  Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study.

Authors:  N B Klarenbeek; S M van der Kooij; M Güler-Yüksel; J H L M van Groenendael; K H Han; P J S M Kerstens; T W J Huizinga; B A C Dijkmans; C F Allaart
Journal:  Ann Rheum Dis       Date:  2010-11-10       Impact factor: 19.103

5.  Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.

Authors:  S M van der Kooij; Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; M Güler-Yüksel; A H Zwinderman; P J S M Kerstens; P A H M van der Lubbe; W M de Beus; B A M Grillet; H K Ronday; T W J Huizinga; F C Breedveld; B A C Dijkmans; C F Allaart
Journal:  Ann Rheum Dis       Date:  2008-07-28       Impact factor: 19.103

6.  Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.

Authors:  Esperanza Naredo; Ingrid Möller; Ana Cruz; Loreto Carmona; Jesús Garrido
Journal:  Arthritis Rheum       Date:  2008-08

Review 7.  After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?

Authors:  Richard J Wakefield; Maria Antonietta D'Agostino; Esperanza Naredo; Maya H Buch; Annamaria Iagnocco; Lene Terslev; Mikkel Ostergaard; Marina Backhaus; Walter Grassi; Maxime Dougados; Gerd R Burmester; Benazir Saleem; Eugenio de Miguel; Cristina Estrach; Kei Ikeda; Marwin Gutierrez; Robert Thompson; Peter Balint; Paul Emery
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

8.  Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis.

Authors:  Andrew Filer; Paola de Pablo; Gina Allen; Peter Nightingale; Alison Jordan; Paresh Jobanputra; Simon Bowman; Christopher D Buckley; Karim Raza
Journal:  Ann Rheum Dis       Date:  2010-11-29       Impact factor: 19.103

9.  Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.

Authors:  Noortje van Herwaarden; Aatke van der Maas; Michiel J M Minten; Frank H J van den Hoogen; Wietske Kievit; Ronald F van Vollenhoven; Johannes W J Bijlsma; Bart J F van den Bemt; Alfons A den Broeder
Journal:  BMJ       Date:  2015-04-09

10.  Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.

Authors:  Shintaro Hirata; Kazuyoshi Saito; Satoshi Kubo; Shunsuke Fukuyo; Yasushi Mizuno; Shigeru Iwata; Masao Nawata; Norifumi Sawamukai; Kazuhisa Nakano; Kunihiro Yamaoka; Yoshiya Tanaka
Journal:  Arthritis Res Ther       Date:  2013-09-25       Impact factor: 5.156

View more
  9 in total

1.  Importance of baseline musculoskeletal ultrasound findings in the prognosis of rheumatoid arthritis.

Authors:  Chao Sun; Xuan Qi; Yushu Yang; Lingyan Lei; Lixia Gao; Huifang Guo
Journal:  Clin Rheumatol       Date:  2022-01-18       Impact factor: 2.980

2.  Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

Authors:  Lise M Verhoef; Bart Jf van den Bemt; Aatke van der Maas; Johanna E Vriezekolk; Marlies E Hulscher; Frank Hj van den Hoogen; Wilco Ch Jacobs; Noortje van Herwaarden; Alfons A den Broeder
Journal:  Cochrane Database Syst Rev       Date:  2019-05-24

Review 3.  The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling.

Authors:  Wida Razawy; Marjolein van Driel; Erik Lubberts
Journal:  Eur J Immunol       Date:  2018-01-15       Impact factor: 5.532

4.  Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.

Authors:  Andreas Kerschbaumer; Alexandre Sepriano; Josef S Smolen; Désirée van der Heijde; Maxime Dougados; Ronald van Vollenhoven; Iain B McInnes; Johannes W J Bijlsma; Gerd R Burmester; Maarten de Wit; Louise Falzon; Robert Landewé
Journal:  Ann Rheum Dis       Date:  2020-02-07       Impact factor: 19.103

5.  Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study.

Authors:  Kenneth F Baker; Andrew J Skelton; Dennis W Lendrem; Adam Scadeng; Ben Thompson; Arthur G Pratt; John D Isaacs
Journal:  J Autoimmun       Date:  2019-07-04       Impact factor: 14.511

6.  Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland.

Authors:  Theresa Burkard; Enriqueta Vallejo-Yagüe; Thomas Hügle; Axel Finckh; Andrea Michelle Burden
Journal:  BMJ Open       Date:  2022-03-15       Impact factor: 2.692

7.  Blood MALT1, Th1, and Th17 cells are dysregulated, inter-correlated, and correlated with disease activity in rheumatoid arthritis patients; meanwhile, MALT1 decline during therapy relates to treatment outcome.

Authors:  Zhuang Ye; Lu Chen; Ying Fang; Ling Zhao
Journal:  J Clin Lab Anal       Date:  2021-11-17       Impact factor: 2.352

8.  DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability.

Authors:  M Verstappen; E van Mulligen; P H P de Jong; A H M van der Helm-Van Mil
Journal:  RMD Open       Date:  2020-05

Review 9.  Defining the Optimal Strategies for Achieving Drug-Free Remission in Rheumatoid Arthritis: A Narrative Review.

Authors:  Hanna Gul; Kate Harnden; Benazir Saleem
Journal:  Healthcare (Basel)       Date:  2021-12-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.